The ability of body lotion containing provitamin D3 to reduce itching in patients with chronic kidney disease undergoing routine hemodialysis

ISRCTN ISRCTN27942151
DOI https://doi.org/10.1186/ISRCTN27942151
Submission date
27/12/2022
Registration date
06/01/2023
Last edited
16/01/2024
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Skin and Connective Tissue Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
Itching (pruritus) is often experienced by patients with chronic kidney disease (CKD) undergoing hemodialysis (HD), resulting in poor sleep quality which can affect the patient's quality of life. Several studies have shown dry skin, decreased vitamin D levels, and increased inflammatory markers (one of which is interleukin-31/IL-31) in CKD patients undergoing HD with itching complaints. Several other studies have shown that the intensity of itching can be reduced by improving skin hydration through the application of body lotion. This study aims to determine the ability of body lotion enriched with provitamin D3 to reduce the intensity of itching in patients with CKD undergoing routine HD.

Who can participate?
CKD patients aged 18-60 years old who have undergone routine hemodialysis two times a week for between 3 months and 10 years, and who have complaints of pruritus

What does the study involve?
Participants would be instructed to apply the randomly assigned body lotion twice a day and to sunbathe twice a week for 4 weeks. A nurse would draw 3 ml of blood at the beginning and the end of the study. Itching intensity and skin hydration are measured at the beginning and after 2, and 4 weeks.

What are the possible benefits and risks of participating?
The possible benefits would be free body lotions and free measurement of skin hydration, vitamin D levels, and IL-31 levels. The possible risks of using body lotion could be itchy, stinging, and/or pain at the site of application, while the risks of venous blood sampling could be phlebitis (inflammation of a vein) and/or thrombophlebitis (blood clot in a vein) at the sampling site

Where is the study run from?
Gadjah Mada University (Indonesia)

When is the study starting and how long is it expected to run for?
November 2021 to June 2023

Who is funding the study?
1. Duta Wacana Christian University (Indonesia)
2. Gadjah Mada University (Indonesia)

Who is the main contact?
Dr Arum Krismi, M.Sc, Sp.KK, penelitian.arumkrismi@gmail.com

Contact information

Ms Arum Krismi
Principal Investigator

Sekar Bakung Residence no. E1
Jl. Imogiri Barat, Semail, Kel. Bangunharjo, Kec. Sewon, Daerah Istimewa Yogyakarta
Bantul
55188
Indonesia

ORCiD logoORCID ID 0000-0003-4276-3025
Phone +62 (0)811254861
Email dr_arumkrismi@staff.ukdw.ac.id

Study information

Study designMulticenter interventional double-blinded randomized controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet 42961_PIS_05Jan23.pdf
Scientific titleCorrelation of changes in pruritus intensity with changes in serum IL-31 levels after application of body lotion enriched with provitamin D3 on patients with chronic kidney disease undergoing routine hemodialysis
Study objectivesBody lotion enriched with provitamin D3 reduced the intensity of chronic kidney disease-associated pruritus on patients undergoing routine hemodialysis
Ethics approval(s)Approved 23/12/2021, Medical and Research Ethics Committee (MHREC) Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada-Dr. Sardjito General Hospital (Gedung Radiopoetro Lt 2 Sayap Barat, Jl. Farmako, Sekip Utara, Yogyakarta, Indonesia, 55128; +62 (0)274 588688 ext. 17225, +62 (0)811 2666 869; mhrec_fmugm@ugm.ac.id), ref: KE/FK/1375/EC/2021
Health condition(s) or problem(s) studiedChronic kidney disease-associated pruritus in patients undergoing routine hemodialysis
InterventionTreatment: body lotion enriched with and without (placebo) provitamin D3
Randomization: simple randomization

Details of interventions:
1. 4 g (equal to 20,000 IU provitamin D3) per day, applied to one arm (1.5 g per application) and about 10 cm² area with the most intense itching (0.5 g per application), applied twice daily after bathing, for 28 days
2. Sunbathing twice weekly on the applicated arm
Intervention typeSupplement
Primary outcome measurePruritus intensity measured using a 24-hours Worst Itching Intensity Visual Analog Scale (WI-VAS) at baseline, 2, and 4 weeks
Secondary outcome measures1. Transepidermal water loss measured using a Tewameter at baseline, 2, and 4 weeks
2. Stratum corneum hydration measured using a corneometer at baseline, 2, and 4 weeks
3. Serum calcidiol levels measured using ELISA at baseline and 4 weeks
4. Serum IL-31 levels measured using ELISA at baseline and 4 weeks
Overall study start date08/11/2021
Completion date30/06/2023

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
Upper age limit60 Years
SexBoth
Target number of participants82
Total final enrolment61
Key inclusion criteria1. 18-60 years old
2. Complaints of pruritus with WI-VAS ≥4
3. Undergoing routine hemodialysis two times a week for ≥3 months and ≤10 years
4. Do not use any topical medical treatment for pruritus for at least 2 weeks before the study started. Medical treatment is medicine given by a doctor, both recorded in the Medical Record (MR) of the subject or recorded by the subject
5. Do not use any self-medication that is topically applied for pruritus for at least 2 weeks before the start of the study. Self-medication is non-medical treatment carried out by the subject alone or given by family, including but not limited to herbal concoctions, special soaps, oils, powders, and others
6. Agree to voluntarily participate in the study by signing the informed consent form
Key exclusion criteria1. Having one or more of the following diseases listed in subject MR and or obtained from anamnesis during subject screening:
1.1. Hepatitis C virus infection
1.2. Primary biliary cirrhosis
1.3. Hodgkin lymphoma
1.4. Cutaneous T-cell lymphoma
1.5. Polycythemia vera
1.6. HIV infection
1.7. Atopic dermatitis
1.8. Drug-induced hypersensitivity
1.9. Insect bites reactions
1.10. Scabies
2. Having an impaired verbal and written communication
3. Having an impaired mobility
Date of first enrolment10/05/2022
Date of final enrolment06/05/2023

Locations

Countries of recruitment

  • Indonesia

Study participating centres

Panti Rapih Hospital
Jl. Cik Di Tiro No.30, Samirono, Terban, Kec. Gondokusuman, Daerah Istimewa Yogyakarta
Yogyakarta
55223
Indonesia
Dr. Sardjito General Hospital
Jl. Kesehatan Jl. Kesehatan Sendowo No.1, Sendowo, Sinduadi, Kec. Mlati, Daerah Istimewa Yogyakarta
Sleman
55281
Indonesia
Bethesda Hospital, Yogyakarta
Jl. Jend. Sudirman No.70, Kotabaru, Kec. Gondokusuman, Daerah Istimewa Yogyakarta
Yogyakarta
55224
Indonesia
PKU Muhammadiyah Hospital of Yogyakarta
Jl. KH. Ahmad Dahlan No.20, Ngupasan, Kec. Gondomanan, Daerah Istimewa Yogyakarta
Yogyakarta
55122
Indonesia
Rumah Sakit Akademik UGM Yogyakarta
Jl. Kabupaten, Kranggahan I, Trihanggo, Kec. Gamping, Daerah Istimewa Yogyakarta
Sleman
55291
Indonesia
PKU Muhammadiyah Hospital of Gamping
Jl. Wates, Jl. Nasional III KM.5,5, Bodeh, Ambarketawang, Kec. Gamping, Daerah Istimewa Yogyakarta
Sleman
55294
Indonesia
Rumah Sakit Umum Daerah (RSUD) Kota Yogyakarta
Jl. Ki Ageng Pemanahan No.1-6, Sorosutan, Kec. Umbulharjo, Daerah Istimewa Yogyakarta
Yogyakarta
55162
Indonesia

Sponsor information

Gadjah Mada University
University/education

Prodi Doktor FK-KMK UGM
Gedung Pascasarjana Tahir, Sayap Utara lantai 3
Jl. Farmako, Sekip Utara, Sendowo, Sinduadi, Mlati, Daerah Istimewa Yogyakarta
Sleman
55281
Indonesia

Phone +62 (0)274 545458
Email s3fk@ugm.ac.id
Website https://s3.fkkmk.ugm.ac.id/
ROR logo "ROR" https://ror.org/03ke6d638

Funders

Funder type

University/education

Universitas Kristen Duta Wacana
Private sector organisation / Universities (academic only)
Alternative name(s)
Duta Wacana Christian University, UKDW Yogyakarta, UKDW, DWCU
Location
Indonesia
Universitas Gadjah Mada
Private sector organisation / Universities (academic only)
Alternative name(s)
Gadjah Mada University, UGM
Location
Indonesia

Results and Publications

Intention to publish date30/06/2024
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planPlanned publication in 'Advances in Chronic Kidney Disease'
IPD sharing planThe datasets generated and/or analysed during the current study are/will be available upon request from Arum Krismi (dr_arumkrismi@staff.ukdw.ac.id). The type of data will be shared as requested in the format of excel, when all of the results are already published for about 5 years since the end of the study, to view only, with other researchers of the same field of study (CKD-associated pruritus), without consent from participants because the data would not contain participants' identity except their age and sex.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Participant information sheet 05/01/2023 05/01/2023 No Yes

Additional files

42961_PIS_05Jan23.pdf

Editorial Notes

16/01/2024: The following changes were made to the trial record:
1. The total final enrolment was added.
2. The study participating centre RSUD Sleman was removed.
05/01/2023: Trial's existence confirmed by the Medical & Health Research Ethics committee (MHREC) Faculty of Medicine, Public Health and Nursing Universitas Gadjah Mada.